ArticleHealth science reports2026
Leonurine: A Multifaceted Bioactive Alkaloid-From Pharmacological Mechanisms to Clinical Translation: A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leonurine (LEO), a bioactive alkaloid derived from the Methods: A structured literature review was conducted using scientific databases including PubMed, Scopus, and Web of Science. Relevant preclinical and clinical studies on LEO were selected based on keywords such as "Leonurine," "pharmacology," "toxicity," and "clinical trials." Data were synthesized to summarize LEO's extraction, biosynthesis, pharmacokinetics, pharmacodynamics, and translational potential. Results: LEO shows rapid absorption but low oral bioavailability (2.21%) due to extensive first-pass metabolism. It preferentially distributes to metabolically active organs such as the liver, kidneys, and heart. Pharmacologically, LEO demonstrates therapeutic efficacy in gynecological, cardiovascular, neurological, and oncological conditions through modulation of oxidative stress, inflammatory mediators, and apoptosis-related pathways. Preclinical studies report a favorable safety profile at therapeutic doses, although toxicity has been observed at higher concentrations, especially with crude extracts. Ongoing formulation efforts such as nanoparticles and prodrugs aim to enhance its pharmacokinetic properties. Conclusion: Leonurine holds considerable promise as a multi-target therapeutic agent. However, successful clinical translation will require structural optimization, improved drug delivery strategies, detailed mechanistic studies, and rigorous human trials. Addressing these gaps may position LEO as a novel candidate in evidence-based phytotherapy and modern drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.